Pulmonary resection after curative intent radiotherapy (> 59 Gy) and concurrent chemotherapy in non–small-cell lung cancer
JR Sonett, M Suntharalingam, MJ Edelman… - The Annals of thoracic …, 2004 - Elsevier
BACKGROUND: Pulmonary resection after chemotherapy and concurrent full-dose
radiotherapy (> 59 Gy) has previously been associated with unacceptably high morbidity …
radiotherapy (> 59 Gy) has previously been associated with unacceptably high morbidity …
Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non–small-cell lung …
DC Betticher, SF Hsu Schmitz, M Tötsch… - Journal of Clinical …, 2003 - ascopubs.org
Purpose: A multicenter, phase II trial investigated the efficacy and toxicity of neoadjuvant
docetaxel-cisplatin in locally advanced non–small-cell lung cancer (NSCLC) and examined …
docetaxel-cisplatin in locally advanced non–small-cell lung cancer (NSCLC) and examined …
Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally …
W Eberhardt, H Wilke, G Stamatis… - Journal of clinical …, 1998 - ascopubs.org
PURPOSE To evaluate the feasibility and efficacy of an intensive multimodality approach
with combination chemotherapy, hyperfractionated accelerated chemoradiotherapy, and …
with combination chemotherapy, hyperfractionated accelerated chemoradiotherapy, and …
[HTML][HTML] Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non–small-cell lung cancer
W Weder, S Collaud, WEE Eberhardt, S Hillinger… - The Journal of thoracic …, 2010 - Elsevier
OBJECTIVE: The mortality of pneumonectomy after chemotherapy or chemoradiotherapy for
locally advanced non–small-cell lung cancer is reported to be as high as 26%. We …
locally advanced non–small-cell lung cancer is reported to be as high as 26%. We …
[HTML][HTML] One hundred consecutive pneumonectomies after induction therapy for non-small cell lung cancer: an uncertain balance between risks and benefits
C Doddoli, F Barlesi, D Trousse, S Robitail… - The Journal of Thoracic …, 2005 - Elsevier
OBJECTIVE: We sought to assess postoperative outcome after pneumonectomy after
neoadjuvant therapy in patients with non-small cell lung cancer. METHODS: This …
neoadjuvant therapy in patients with non-small cell lung cancer. METHODS: This …
Risks of neoadjuvant chemotherapy and radiation therapy
G Stamatis - Thoracic surgery clinics, 2008 - Elsevier
The aim of the present contribution is to overview the literature and to evaluate the risks for
medical and surgical complications of lung cancer surgery after induction chemotherapy or …
medical and surgical complications of lung cancer surgery after induction chemotherapy or …
Pneumonectomy after high-dose radiation and concurrent chemotherapy for nonsmall cell lung cancer
BDT Daly, HC Fernando, A Ketchedjian… - The Annals of thoracic …, 2006 - Elsevier
BACKGROUND: Pneumonectomy after high-dose radiotherapy and concurrent
chemotherapy has been associated with high operative mortality. Therefore, most induction …
chemotherapy has been associated with high operative mortality. Therefore, most induction …
[HTML][HTML] Propofol improves sensitivity of lung cancer cells to cisplatin and its mechanism
Y Huang, L Lei, Y Liu - … medical journal of experimental and clinical …, 2020 - ncbi.nlm.nih.gov
Background Cisplatin (cis-diamminedichloroplatinum, DDP) resistance is identified as the
primary obstacle during lung cancer treatment, while DDP resistance is exist extensively …
primary obstacle during lung cancer treatment, while DDP resistance is exist extensively …
Preoperative chemotherapy for lung cancer does not increase surgical morbidity
MP Siegenthaler, KM Pisters, KW Merriman… - The Annals of thoracic …, 2001 - Elsevier
Background. Preoperative chemotherapy (C+ S) for non–small cell lung cancer (NSCLC)
has increased in an attempt to improve survival. Patients receiving C+ S potentially may …
has increased in an attempt to improve survival. Patients receiving C+ S potentially may …
Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial
N Girard, F Mornex, JY Douillard, N Bossard, E Quoix… - Lung Cancer, 2010 - Elsevier
Locally advanced non-small cell lung cancers share a risk of both local and systemic
recurrence and justifies a therapeutic strategy combining focal and systemic treatment. In …
recurrence and justifies a therapeutic strategy combining focal and systemic treatment. In …